2026/04/13
TaiMed Biologics (4147) Board Approves Private Placement to Bring in Strategic Investors，Accelerating Global Licensing of Innovative Drugs and Aligning with International Capital Markets
2026/04/10
TaiMed Biologics (4147) CEO Dr. Jimmy Chang Invited to Attend the “19th QIC CEO Week” in Singapore, Engaging with Leading Global Institutional Investors
2026/04/07
TaiMed Biologics (4147) Trogarzo® Qualifies for Zero Tariff Treatment Under U.S. Section 232 Policy with Orphan Drug Designation and Friend-Shoring Supply Chain Advantage
2026/04/07
TaiMed Biologics (4147) TMB-365/380 Phase 2b Enrollment Surpasses 80%, with Peak Annual Sales Potential of Up to US$4 Billion
2026/03/26
TaiMed Biologics(4147) TMB-365/380 Impresses at CROI; Global Pharma Initiates Engagement, First Patient to Receive Third Dose in April
2026/03/23
TaiMed Biologics’TMB-365/380 Advances Ahead of Schedule in Phase 2b; World's Only“No-Screening”Advantage Attracts Strong Global Licensing Interest
2026/03/19
TaiMed Biologics (TPEX: 4147) Leading the Transformation of HIV Treatment — CEO Dr. Jimmy Chang Unveils Platform Strategy for Precision Immunotherapy
2026/03/13
TaiMed Biologics (TPEX: 4147) Leading the Transformation of HIV Treatment — CEO Dr. Jimmy Chang Unveils Platform Strategy for Precision Immunotherapy
2026/03/09
TaiMed Biologics (TPEX: 4147) to Deliver Featured Presentation at the“2026 Taiwan Biotechnology & Healthcare Forum,” Demonstrating R&D Strength and Confidence in Future Growth
2026/02/25
TaiMed Biologics (4147) Confirms Trogarzo® Exports to the U.S. Remain Subject to “Zero Tariff,” Unaffected by Newly Announced Section 122 Tariff Measures
2026/02/10
TaiMed Biologics (4147) Invited to J.P. Morgan Healthcare Conference,Unveils Strategic Expansion from HIV Leadership to Autoimmune Therapies, Targeting a USD 470 Billion Market Opportunity
2026/01/20
[Interview]《PharmaBoardroom》Dr. Jimmy Chang, CEO of TaiMed, shares insights on how CD4-targeted platforms are expanding into autoimmune diseases and precision medicine through ADC technology.
2026/01/07
TaiMed Biologics (4147) Unveils Strategic Blueprint at Investor Conference: TMB-365/380 Enters Value Inflection Phase; First-in-Class CD4-Targeted ADC Expands into the USD 400 Billion Autoimmune Disea